Repurposing host-based therapeutics to control coronavirus and influenza virus

Li, Cui Cui; Wang, Xiao Jia; Wang, Hwa Chain Robert

doi:10.1016/j.drudis.2019.01.018

Cited by 69 publications

(65 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, what we have learnedf rom several medicinal chemistry studies on SARS-CoV and the Middle East Respiratory Syn-drome (MERS-CoV) mayb ed irectly used to help us treat 2019-nCoV.C oV relies on its spike proteins to bind ah ost cell-surface receptor fore ntry ( Figure 1). Most compounds discussedw ill be experimental compounds and drug candidates; for ar eview of repurposed drugs for treating coronaviruses and other viruses,s ee Li et al [7] As little is known so far about the virulence of this virus, we shall also discuss the interactions between spike and ACE2 that might challenget he current view that 2019-nCoV is less virulent than SARS-CoV owing to weaker interactions between spike and ACE2. [3] After the virus' entry into the host cell, its positive genomic RNA attaches directly to the hostr ibosome for the translation of two large, coterminal polyproteins that are processed by proteolysis into components for packaging new virions.…”

Section: Introductionmentioning

confidence: 99%

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV

et al. 2020

View full text Add to dashboard Cite

With the current trajectory of the 2019‐nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better‐studied cousin, SARS‐CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA‐dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS‐CoV. Herein, we suggest four potential drug candidates (an ACE2‐based peptide, remdesivir, 3CLpro‐1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019‐nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad‐spectrum anti‐coronaviral agents for future epidemics.

show abstract

Section: Introductionmentioning

confidence: 99%

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This study also proposes a putative mechanism of action of ibrutinib based on phosphoproteomics data which involves several host factors, including EPHA2, C-JUN and NWASP [223]. Additionally, Li (2019) also reviewed host based therapeutics were effective against corona virus and influenza virus infections [224].…”

Section: Drug Repurposing For Infectious Diseasesmentioning

confidence: 99%

Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work

Kumar

Harilal

Gupta

et al. 2019

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

a b s t r a c tDrug discovery and development are long and financially taxing processes. On an average it takes 12e15 years and costs 1.2 billion USD for successful drug discovery and approval for clinical use. Many lead molecules are not developed further and their potential is not tapped to the fullest due to lack of resources or time constraints. In order for a drug to be approved by FDA for clinical use, it must have excellent therapeutic potential in the desired area of target with minimal toxicities as supported by both pre-clinical and clinical studies. The targeted clinical evaluations fail to explore other potential therapeutic applications of the candidate drug. Drug repurposing or repositioning is a fast and relatively cheap alternative to the lengthy and expensive de novo drug discovery and development. Drug repositioning utilizes the already available clinical trials data for toxicity and adverse effects, at the same time explores the drug's therapeutic potential for a different disease. This review addresses recent developments and future scope of drug repositioning strategy.

show abstract

“…Drug repurposing offers a potentially faster approach to identify drugs that are already approved for other uses and might work for the disease of interest [57][58][59]. This type of strategy was attempted for MERS-CoV and SARS-CoV [60,61] and the repurposing of hostbased therapies has also been proposed for coronaviruses [62]. Several studies have screened a few hundred molecules and tested the activity against MERS-CoV and SARS-CoV (Table 2) [63,64].…”

Section: Mers and Sars Repurposingmentioning

confidence: 99%